Close this search box.
fda guide

FDA Introduces Draft Guidance for Platform Technologies: A New Pathway to Fast-Track Cell and Gene Therapy Approvals

The FDA unveiled a much-anticipated draft guide, outlining how businesses can secure approvals for platform technologies. This regulatory advance has the potential to fast-track the FDA’s ‘platform technology’ procedure, potentially accelerating the endorsement of cell and gene therapies.

Keen to find out more? This comprehensive 15-page draft guide provides a wealth of knowledge for biopharma companies. It sheds light on how to utilize accumulated data such as stability data or inspection outcomes from platform technologies, eliminating the need for product-specific evaluations for certain endpoints. The FDA’s latest draft guide aims to accelerate the approval process for cell and gene therapies using shared technologies. 

This development can significantly fast-track gene therapies using the standard AAV backbone, thus expediting the approval rate. According to Nicole Verdun, who leads the FDA’s newly inaugurated Office of Therapeutic Products, the expectation is for approximately 10 designation requests annually, according to the Federal Register notice.

With a platform technology designation, major benefits await drug corporations. This includes opportunities for earlier and increased engagement with the FDA regarding the application of a platform technology. The designation also allows previously submitted data to be used in future submissions for new drugs or biologics license applications from the same promoter.

In simple terms, platform technology is an efficient, adaptable, and profitable method used in the production or advancement of multiple drugs. This covers lipid nanoparticle platforms for mRNA vaccines or gene therapy products, platforms for various oligonucleotides, and monoclonal antibody platforms.

It’s worth noting that obtaining a platform technology designation does not preclude companies from enjoying the benefits of fast-tracked approvals or other expedited paths. Stay tuned to learn more about this exciting development in the biopharmaceutical industry.

We break it down below:

What Biopharma Companies Need to Know About the Draft Guidance

The draft guidance is not just a regulatory document; it’s a blueprint for faster drug development and approval. Here are some critical points biopharma professionals need to focus on:

  1. Utilizing Existing Data: Companies can reuse data from previously approved platform technologies, such as stability data and inspection outcomes. This reduces the need for repetitive evaluations and speeds up the approval process.
  2. Increased Engagement with the FDA: With a platform technology designation, companies can engage earlier and more frequently with the FDA. This ongoing dialogue helps to address potential regulatory issues sooner, paving the way for smoother approvals.
  3. Expedited Approval Rates: The draft guidance aims to fast-track gene therapies using standard AAV backbones, among other technologies. This could significantly increase the rate of approvals for new treatments.

How Platform Technology Designation Works

Securing a platform technology designation offers several advantages for biopharma companies:

  • Reusability of Data: Once a platform technology is designated, data from its use can be applied to future submissions for new drugs or biologics license applications from the same sponsor.
  • Streamlined Regulatory Process: The designation simplifies the regulatory process, making it easier to navigate and less time-consuming.
  • Cost Efficiency: By reducing the need for repetitive evaluations, companies can save both time and resources, making the drug development process more cost-effective.

Key Benefits for Drug Corporations

The new draft guidance offers several significant benefits for drug corporations:

  1. Earlier FDA Engagement: Companies can start engaging with the FDA earlier in the development process, helping to identify and address potential issues sooner.
  2. Reduced Redundancy: The ability to reuse data from existing platform technologies eliminates redundancy, making the approval process more efficient.
  3. Faster Time to Market: By streamlining the regulatory process, the draft guidance allows companies to bring new therapies to market faster, benefiting patients who need them most.

The Future of Cell and Gene Therapies

The FDA’s draft guidance marks a significant step forward in the regulatory landscape for cell and gene therapies. By recognizing the value of platform technologies, the FDA is paving the way for faster, more efficient drug approvals. This not only benefits biopharma companies but also the patients who rely on these innovative treatments.

Images used under license by vladstar /